enoxacin

(redirected from Penetrex)

enoxacin

 [ĕ-nok´sah-sin]
an antibacterial effective against many gram-positive and gram-negative bacteria; administered orally in the treatment of gonorrhea and urinary tract infections.

enoxacin

/enox·a·cin/ (ĕ-nok´sah-sin) a synthetic antibacterial effective against many gram-positive and gram-negative bacteria.

enoxacin

[ĕ-nok′säsin]
an antibacterial effective against many gram-positive and gram-negative bacteria, administered orally in the treatment of gonorrhea and urinary tract infections.

Bactidron

A fluoroquinolone which is no longer available in the US and many developed nations.

enoxacin

Antibiotics A broad-spectrum–gram-negative bacilli, staphylococci–fluoroquinolone with ↓ activity against streptococci and anaerobes. See Fluoroquinolone.

enoxacin

(enok´səsin),
n brand name: Penetrex;
drug class: fluoroquinolone antiinfective;
action: a broad-spectrum bactericidal agent that inhibits the enzyme deoxyribo-nucleic acid (DNA) gyrase, needed for replication of DNA;
uses: uncomplicated urethral or cervical gonorrhea, uncomplicated and complicated urinary tract infections.

enoxacin

a fluoroquinolone antibiotic, similar to ciprofloxacin.
References in periodicals archive ?
Plumr Penetrex, Drano, Drano Dual Force, Drano Snake Plus,
If your doctor chooses a fluoroquinolone drug (other drugs in this class besides Cipro include Avelox, Floxin, Levaquin, Maxaquin, Noroxin, Penetrex, Tequin, and Zagam) consider cutting back on the intensity of your training and be sure to monitor and report any orthopedic pain to your doctor.
The bill will also prevent competition for other critical drugs, including Cardiogen 82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infection) and Relafen (arthritis).
Other drugs covered by the bill that would continue to be sold free of price-dropping competition are: Cardiogen-82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections) and Relafen (arthritis).
Seniors will be especially harmed by the "Claritin Patent Extension Act" because 35 percent of older Americans pay out-of-pocket for medicine and use most of the drugs protected under the bill, including: Cardiogen-82 (radiologic imaging), Claritin (allergies), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections) and Relafen (arthritis).
Seniors will be hardest-hit because 35 percent of older Americans pay out-of-pocket for medicine and use most of the drugs protected under the bill, including: Cardiogen-82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections), and Relafen (arthritis).
1172 passes because 35 percent of older Americans pay out- of-pocket for medicine and use most of the drugs protected under the bill, including: Cardiogen-82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections) and Relafen (arthritis).
Seniors will be hardest hit because 35 percent of older Americans pay out-of-pocket for medicine and use most of the drugs protected under the bill, including: Cardiogen-82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections), and Relafen (arthritis).
Drugs protected under the bill include Claritin and Eulexin (prostate cancer/Schering-Plough), Daypro (arthritis/Monsanto), Dermatop (skin ailments/Hoechst Marion Roussel), Penetrex (urinary tract infections/Rhone-Poulenc-Rorer), Cardiogen-82 (radiologic imaging/Bristol-Myers Squibb), Nimotop (stroke/Bayer A.
The drugs include Claritin and Eulexin (prostate cancer/Schering-Plough), Dermatop (skin ailments/Hoechst Marion Roussel), Penetrex (urinary tract infections/Rhone- Poulenc-Rorer), Cardiogen-82 (radiologic imaging/Bristol-Myers Squibb), Nimotop (stroke/Bayer A.
Under the terms of the agreement, RPR will assume responsibility for all manufacturing and marketing of Penetrex in the North American market, including the United States, Canada and Puerto Rico.
Announced it had received FDA approval to market three drugs: the ACE inhibitor antihypertensive Accupril; Nipent, for the treatment of hairy cell leukemia in adult patients who are resistant to standard therapy; and Penetrex, an oral quinolone anti-infective.